-- 
Equinox, Medifast, Pluristem, RadVision, SodaStream: U.S. Equity Movers

-- B y   L u   W a n g   a n d   J e f f   K e a r n s
-- 
2011-04-04T20:20:47Z

-- http://www.bloomberg.com/news/2011-04-03/abbott-carnival-corp-general-electric-u-s-equity-preview.html
Shares of the following companies
had unusual moves in U.S. trading. Stock symbols are in
parentheses and share prices are as of 4 p.m. in  New York .  Ambassadors International Inc. (AMIE)   plunged 77
percent, the most since its initial public offering in 1995, to
65 cents. The operator of Windstar Cruises sought  bankruptcy
protection  to sell its assets after losing money in seven out of
the last eight quarters.  Epicor Software Corp. (EPIC)   jumped 12 percent to
$12.56, the highest price since February 2008. The supplier of
business programs said it agreed to be acquired by funds advised
by  Apax Partners  for $12.50 a share in cash.  Equinox Minerals Ltd. (EQN)   rallied 31 percent to
$7.79, the highest price since May 2005. Minmetals Resources
Ltd., the Hong Kong unit of  China ’s biggest metals trader, said
it will bid C$7 a share in cash for the mining company.  General Dynamics Corp. (GD)   slumped 5.2 percent to
$73.37 for the biggest retreat in the  S&P 500 . Gulfstream
Aerospace Corp., a unit of the  Falls Church , Virginia-based
defense company, said four employees died today when a
Gulfstream G650 crashed this morning in Roswell,  New Mexico ,
during performance tests.  LaBarge Inc. (LB)   rose 9.2 percent to $19.03, the
highest price since August 2005. The maker of electronics agreed
to be bought by  Ducommun Inc. (DCO)  , a provider of
engineering and manufacturing services to the aerospace and
defense industry, for $19.25 a share in cash. Ducommun added 3.8
percent to $24.98.  McCormick & Schmick’s Seafood Restaurants Inc. (MSSR)  
rose the most in the Russell 2000 Index, surging 29 percent to
$9.22. Tilman J. Fertitta, who owns about 10.1 percent of the
stock, said he is offering to buy the rest of the shares of the
restaurant chain for $9.25 each.  Medifast Inc. (MED)   fell 7.9 percent to $16.58, the
lowest price since August 2009. The provider of weight loss
programs said in an April 1 statement that it reduced 2008 and
2009 profit by 4 cents a share because of accounting errors in
expense recording.  Molycorp Inc. (MCP)   jumped 12 percent to $66.41, the
highest price since it went public in July 2010. The owner of
the world’s largest rare-earth deposit outside China said its
unit Molycorp Minerals LLC completed the purchase of 90 percent
of AS Silmet in a deal valued at $89 million.  OmniVision Technologies Inc. (OVTI)   dropped 7.4 percent
to $33.50 for the biggest decline since Feb. 23. Sony Corp.
(6758 JP) may supply cameras for Apple Inc.’s (AAPL US) iPhone
5, the blog Electronista said, after Sony Chief Executive
Officer Howard Stringer told the Wall Street Journal that
shipments of sensors to Apple would be delayed. Apple has
sourced cameras only from OmniVision to date, Electronista said.  Pluristem Therapeutics Inc. (PSTI)   rose 15 percent, the
most since Jan. 25, to $2.96. The developer of cell-therapy
products was rated “buy” in new coverage by Needham & Co.  RadVision Ltd. (RVSN)   fell 17 percent, the most since
October 2009, to $9.96. The maker of video-conferencing systems
said lower-than-expected sales to Cisco Systems Inc. would
result in a wider first-quarter loss than it forecast in
February.  SodaStream International Ltd. (SODA)   declined 8.8
percent, the most since March 1, to $42.70. The producer of soda
makers said Swedish antitrust authorities indicated they would
send it a draft antitrust complaint in a case concerning the use
of carbon dioxide cylinders.  Vivus Inc. (VVUS)   advanced 6.7 percent, the most since
Jan. 31, to $6.73. The biopharmaceutical company’s experimental
diet pill Qnexa helped patients lower their blood pressure and
cholesterol after two years, additional benefits that may help
persuade U.S. regulators to approve the medicine.  Orexigen Therapeutics Inc. (OREX)  , which is also
developing prescription diet pill, said additional data that
showed that overweight and obese patients treated with its
Contrave maintained normal 24-hour circadian patterns over one
year of treatment. The stock climbed 14 percent to $3.29.  To contact the reporters on this story:
Lu Wang in New York at 
 lwang8@bloomberg.net ;
Jeff Kearns in New York at 
 jkearns3@bloomberg.net   To contact the editor responsible for this story:
Nick Baker at 
 nbaker7@bloomberg.net  